Answers are grounded in this paper and cite their sources.
Accurate prognostication in critically ill patients remains a central challenge. This study aimed to explore serum proteomic changes associated with the near-death state and to evaluate candidate biomarkers. We conducted a two-phase study, beginning with data-independent acquisition mass spectrometry (DIA-MS) on a discovery cohort of patients with acute cerebral infarction ( n = 6). Candidate biomarkers were then evaluated via ELISA in an independent, heterogeneous cohort of critically ill neurological patients ( n = 60). Exploratory proteomic profiling suggested broad molecular differences between the near-death and stable states, although no protein remained statistically significant after multiple-testing correction in the small discovery cohort. Candidate prioritization nevertheless identified Solute Carrier Family 3 Member 2 (SLC3A2) for downstream validation. Serum SLC3A2 concentrations were higher in near-death patients than in stable controls ( P = 0.008) and showed moderate discrimination between the two states (AUC = 0.722). After adjustment for APACHE II, the association of SLC3A2 with ND status was not statistically significant, and its addition did not significantly improve model discrimination. Exploratory decision-curve analysis suggested possible net-benefit advantages over selected threshold probabilities. In conclusion, exploratory proteomic analysis identified nominal protein-level differences associated with the near-death state. SLC3A2 emerged as a candidate biomarker that may complement existing clinical scoring systems, although its incremental and independent prognostic value requires confirmation in larger external cohorts.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: